Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018.
Tag Archives: Cannabinoid
CBD—a purified weed extract that won’t get you stoned—is used to treat everything from breast cancer to stress relief, epilepsy to aching joints. VICE met up with David Bonvillain, who runs the CBD company Elite Botanicals, for an inside scoop on the extract’s “limitless future.”
From WEEDIQUETTE’s “Chronic Trauma” episode: Krishna accompanies rapper JohnboyCOOL to learn about medicinally treating his trauma with cannabis.
BATON ROUGE,La., July 18, 2017 /Weed Wire/ — Dewmar International BMC, Inc. (OTC PINK: DEWM) announced today that it has filed a provisional patent with the United States Patent and Trademark Office for the treatment of lung cancer with cannabinoids.
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.
Medical Marijuana, Inc. holds the distinction of being the first publicly listed marijuana stock, and its diversity is rare, but is it worth investing in?
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
Owners of pets who suffer from arthritis and a loss of appetite are looking towards hemp pills in an effort to ease their animals’ pain.
Cara Therapeutics has been phenomenal over the past couple of years, and it’s rightfully beginning to catch the attention of marijuana stock investors.
Last week, two marijuana stocks skyrocketed by a double-digit percentage. Let’s take a closer look at the possible “why” behind these moves.
The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.
TORONTO, Ontario, May 16, 2017 /Weed Wire/ — Alternate Health Corp. (CSE:AHG, OTC:AHGIF), a diverse healthcare company revolutionizing patient care and research in the emerging medical cannabis industry, announced today the completion of its initial study to demonstrate the effectiveness of cannabinoids in treating chronic post-Zika virus symptoms.
These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.
Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.
Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.
Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, but these efforts at discrediting cannabis stop at the U.S. border.
DENVER, March 15, 2017 /Weed Wire/ — IMPACT Network, a nonprofit dedicated to Improving Marijuana Policy and Accelerating Cannabinoid Therapeutics, announced their new focus on cannabis for women’s health, as well as several new executive team appointments that will support Founder and Executive Director, Dr. Michele Ross, and newly promoted Deputy Executive Director Susan Parker.
President of Evoxe Laboratories, Michael Katz, presents this emerging brand’s business model that lead to its current success.
The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, for treating glioblastoma multiforme, or GBM.
DENVER, Jan. 16, 2016 /Weed Wire/ — Hoban Law Group has filed a petition in San Francisco’s United States Court of Appeals for the Ninth Circuit to challenge what appears to be the DEA’s attempt to control an otherwise lawful substance.
As Cannabis Science Inc (OTCMKTS:CBIS) goes forward into 2017 with its stock, the company recently announced about its new drug facility in Nevada.
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
VANCOUVER, British Columbia, Dec. 20, 2016 /Weed Wire/ — ICC International Cannabis Corporation (“ICC” or the “Company”) (TSXV: ICC) has entered into an agreement to lease approximately 9 hectares of additional land adjacent to the Company’s existing property used for the production of cannabinoid extracts and by-products for medicinal use and industrial hemp.
If you’re considering investing in marijuana stocks in the new year, here are five numbers you should know before taking the plunge.
From children with seizures to athletes with joint pain, people are using cannabis to cope effectively. This one herb and its variety of therapeutic compounds seem to affect every aspect of our bodies and minds. How is this possible?
MediPen, a cannabis vaporizer, is being tested by the United Kingdom’s National Health Service, according to an Aug. 15, 2016, article in The Independent. It’s the first time a cannabis-based product has been tested by the NHS.
DENVER, May 11, 2016 /Weed Wire/ — Dixie Brands Inc. (Dixie), a leader in emerging cannabinoid extraction and wellness platforms, announces the expansion of its Aceso line of products with the launch of a delicious, dissolvable effervescent drink mix featuring hemp-derived cannabinoids, boosted with all-natural vitamins and terpenes.
SAN DIEGO, March 15, 2016 /Weed Wire/ — As more states decriminalize recreational use of marijuana and expand its medical applications, concern is growing about inconsistent and inaccurate dosage information listed on many products, including brownies and other edibles.
KELOWNA, British Columbia, Feb. 19, 2016 /Weed Wire/ — Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) announces that at the Annual General Meeting expected to be held March 23, 2016, the Company proposes to change its name to Lexaria Bioscience Corp.
COLORADO SPRINGS, Colo., Feb. 8, 2016/ Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced its next critical ailment target is autism and brings Mieko Hester-Perez on its Scientific Advisory Board to lead this charge.
DENVER, Jan. 8, 2015 /Weed Wire/ — The second free IMPACT event on Seniors and Cannabis will be held on Saturday, January 9th, from noon to 5 pm at Green Labs in Denver’s RiNo district.
DOWNERS GROVE, Ill., Dec. 7, 2015 /WeedWire/ — Revolution Cannabis Analytics will document the choices, attitudes, and experience of medical cannabis patients in Illinois in a first-of-its-kind study.
The Endocannabinoid Deficiency Foundation will officially become the Impact Network on November 1, 2015.
Zynerba presented the status of its research program at BIO Investor Forum. This is a 14-year-old annual biotech gathering, with roughly 600 attendees from 21 countries, and the presentation, in San Francisco, looked likely to be a big event in this company’s development.
KELOWNA, B.C., July 7, 2015 /Weed Wire/ – Lexaria Corp. (CSE: LXX) (OTCQB: LXRP), a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technology, today announced the release of its official press kit providing media partners with detailed information about the company and its technologies, as well as high resolution images and other assets to assist with content creation.
About seven residents at a District of Columbia homeless shelter were hospitalized last week after overdosing on a synthetic marijuana product. Synthetics are making more people sick.
Last Wednesday, two pain specialists that were top subscribers of Insys Therapeutics’ (NASDAQ: INSY) leading prescription therapy Subsys were arrested, as part of a year-long operation by the DEA.
As a newcomer to the legal cannabis space, the alphabet soup of chemical chemotypes, or distinct chemical compounds, can be overwhelming. These abbreviations should not be dismissed because they indicate the chemical composition of cannabis plants.
The Federal Drug Administration is willing to support continued research into a treatment option that is based on Dronabinol, a cannabinoid, which is one of the many non-THC derivatives of the cannabis plant.
MyDx is a handheld device straight out of a Star Trek episode. Simply place a small amount of cannabis into it’s sensor and watch as your smart phone is illuminated with information about the plant.
CannaSafe Analytics (CSA LABS) is the only national ISO17025:2005 accredited cannabis testing laboratory. CannaSafe’s accredited scope includes full cannabinoid and terpenoid profiling, microbiological, heavy metals, pesticide contamination, plant growth regulars and residual solvents.
Cannabinoid research company, Cannabis Therapy Corp., is expected to present at an upcoming cannabis summit in Denver.
Some Americans risk their lives with K2, a dangerous chemical alternative, because using marijuana leaves evidence in the bloodstream.
GW Pharma utilizies CBD technology in order to develop a new breakthrough treatment for pediatric epilepsy.